Inefficacy of anti-VEGF therapy reflected in VEGF-mediated photoreceptor degeneration
Retinal neovascularization (RNV) is primarily driven by vascular endothelial growth factor (VEGF). However, current anti-VEGF therapies are limited by short half-lives and repeated injections, which reduce patient quality of life and increase medical risks. Additionally, not all patients benefit fro...
Saved in:
Main Authors: | Xin Xu (Author), Ni Han (Author), Fangkun Zhao (Author), Ruoyue Fan (Author), Qingguo Guo (Author), Xuefei Han (Author), Ying Liu (Author), Guangzuo Luo (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
by: Laura García-Quintanilla, et al.
Published: (2019) -
Pharmacoeconomic analysis of anti-VEGF therapy for age-related macular degeneration
by: A. E. Cheberda, et al.
Published: (2018) -
Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
by: Kaiser SM, et al.
Published: (2021) -
Resolvin D1 Modulates the Intracellular VEGF-Related miRNAs of Retinal Photoreceptors Challenged With High Glucose
by: Rosa Maisto, et al.
Published: (2020) -
Corrigendum: Resolvin D1 Modulates the Intracellular VEGF-Related miRNAs of Retinal Photoreceptors Challenged With High Glucose
by: Rosa Maisto, et al.
Published: (2020)